PL2038265T3 - Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania - Google Patents

Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania

Info

Publication number: PL2038265T3
Authority: PL; Poland
Prior art keywords: methods; human protein; tyrosine phosphatase; phosphatase inhibitors; inhibitors
Prior art date: 2006-06-27

Application number

PL07809908T

Other languages

English (en)

Inventor

Jeffrey Lyle Gray

Kande Amarasinghe

Cynthia Monesa Clark

Matthew Brian Maier

Ryan Nichols

Original Assignee

Aerpio Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-27

Filing date

2007-06-27

Publication date

2015-07-31

2007-06-27 Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc

2015-07-31 Publication of PL2038265T3 publication Critical patent/PL2038265T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
AIDS & HIV (AREA)
Neurology (AREA)
Epidemiology (AREA)

PL07809908T 2006-06-27 2007-06-27 Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania PL2038265T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US81673106P	2006-06-27	2006-06-27
US81673006P	2006-06-27	2006-06-27
US81682506P	2006-06-27	2006-06-27
EP07809908.2A EP2038265B1 (en)	2006-06-27	2007-06-27	Human protein-tyrosine phosphatase inhibitors and methods of use
PCT/US2007/014823 WO2008002570A2 (en)	2006-06-27	2007-06-27	Human protein tyrosine phosphatase inhibitors and methods of use

Publications (1)

Publication Number	Publication Date
PL2038265T3 true PL2038265T3 (pl)	2015-07-31

Family

ID=38704715

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07809908T PL2038265T3 (pl)	2006-06-27	2007-06-27	Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania

Country Status (20)

Country	Link
US (3)	US7795444B2 (pl)
EP (3)	EP3293182A1 (pl)
JP (6)	JP5261383B2 (pl)
KR (1)	KR101179087B1 (pl)
AU (1)	AU2007265454B2 (pl)
BR (1)	BRPI0713357A2 (pl)
CA (1)	CA2657107C (pl)
CO (1)	CO6150140A2 (pl)
CY (1)	CY1116377T1 (pl)
DK (1)	DK2038265T3 (pl)
ES (1)	ES2534392T3 (pl)
HK (1)	HK1129387A1 (pl)
HU (1)	HUE024976T2 (pl)
IL (1)	IL196129A (pl)
MX (1)	MX2009000289A (pl)
NZ (1)	NZ574406A (pl)
PL (1)	PL2038265T3 (pl)
PT (1)	PT2038265E (pl)
SI (1)	SI2038265T1 (pl)
WO (1)	WO2008002570A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7226755B1 (en) *	2002-09-25	2007-06-05	The Procter & Gamble Company	HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) *	2002-09-25	2009-03-24	The Proctor & Gamble Company	Three dimensional coordinates of HPTPbeta
KR20110122881A (ko)	2006-04-07	2011-11-11	워너 칠콧 컴퍼니 엘엘씨	인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US8846685B2 (en)	2006-06-27	2014-09-30	Aerpio Therapeutics Inc.	Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en)	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) *	2006-06-27	2013-01-24	Aerpio Therapeutics Inc.	Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) *	2006-06-27	2009-09-15	Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) *	2006-06-27	2010-09-14	Warner Chilcott Company	Human protein tyrosine phosphatase inhibitors and methods of use
CN102365023A (zh) *	2009-01-12	2012-02-29	阿克比治疗有限公司	治疗血管渗漏综合征的方法
AU2016203254B2 (en) *	2009-01-12	2018-09-13	EyePoint Pharmaceuticals, Inc.	Methods for treating vascular leak syndrome
AU2014202211B2 (en) *	2009-01-12	2016-06-02	EyePoint Pharmaceuticals, Inc.	Methods for treating vascular leak syndrome
US9096555B2 (en)	2009-01-12	2015-08-04	Aerpio Therapeutics, Inc.	Methods for treating vascular leak syndrome
PT2451279T (pt)	2009-07-06	2019-06-18	Aerpio Therapeutics Inc	Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas
US8883832B2 (en)	2009-07-06	2014-11-11	Aerpio Therapeutics Inc.	Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2496236B1 (en)	2009-11-06	2013-05-01	Aerpio Therapeutics Inc.	Prolyl hydroxylase inhibitors
JP2013539756A (ja) *	2010-10-07	2013-10-28	アエルピオセラピューティックスインコーポレイテッド	眼球浮腫、血管新生および関連疾患を処置するための組成物および方法
WO2013056233A1 (en)	2011-10-13	2013-04-18	Aerpio Therapeutics, Inc.	Treatment of ocular disease
CA2850830A1 (en)	2011-10-13	2013-04-18	Aerpio Therapeutics, Inc.	Methods for treating vascular leak syndrome and cancer
US9962362B2 (en) *	2012-03-29	2018-05-08	Children's Hospital Medical Center	Use of small molecule inhibitors targeting EYA tyrosine phosphatase
AU2014205317B2 (en) *	2013-01-09	2016-11-24	Gilead Sciences, Inc.	5-membered heteroaryls and their use as antiviral agents
US9725430B2 (en)	2013-01-16	2017-08-08	Children's Hospital Medical Center	Use of small molecule inhibitors targeting EYA tyrosine phosphatase
BR112015023753A2 (pt)	2013-03-15	2017-07-18	Aerpio Therapeutics Inc	composições, formulações e métodos para o tratamento de doenças oculares
US20150050277A1 (en)	2013-03-15	2015-02-19	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular diseases
US9388135B2 (en)	2014-02-19	2016-07-12	Aerpio Therapeutics, Inc.	Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
CN106456614A (zh)	2014-03-14	2017-02-22	爱尔皮奥治疗有限公司	HPTP‑β抑制剂
US9539245B2 (en)	2014-08-07	2017-01-10	Aerpio Therapeutics, Inc.	Combination of immunotherapies with activators of Tie-2
WO2016189877A1 (en) *	2015-05-27	2016-12-01	Kyorin Pharmaceutical Co., Ltd.	Urea derivative or pharmacologically acceptable salt thereof
ES2981607T3 (es)	2015-09-23	2024-10-09	Eyepoint Pharmaceuticals Inc	Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
JP6690282B2 (ja)	2016-02-15	2020-04-28	住友電気工業株式会社	炭化珪素エピタキシャル基板および炭化珪素半導体装置の製造方法
AU2017299581B2 (en)	2016-07-20	2024-05-23	EyePoint Pharmaceuticals, Inc.	Humanized monoclonal antibodies that target ve-ptp (hptp-β)
US10894824B2 (en)	2018-09-24	2021-01-19	Aerpio Pharmaceuticals, Inc.	Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US11253502B2 (en)	2019-04-29	2022-02-22	EyePoint Pharmaceuticals, Inc.	Tie-2 activators targeting the Schlemm's canal
US11413242B2 (en)	2019-06-24	2022-08-16	EyePoint Pharmaceuticals, Inc.	Formulations of Tie-2 activators and methods of use thereof
US11613534B2 (en)	2019-10-29	2023-03-28	EyePoint Pharmaceuticals, Inc.	Small molecule activators of Tie-2
CN117460743A (zh) *	2020-06-16	2024-01-26	曼宁研究公司	小分子ve-ptp抑制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4673641A (en)	1982-12-16	1987-06-16	Molecular Genetics Research And Development Limited Partnership	Co-aggregate purification of proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP1225226B1 (en)	1992-03-13	2007-12-05	bioMerieux B.V.	Peptides and nucleic acid sequences related to Epstein Barr Virus
US5770565A (en)	1994-04-13	1998-06-23	La Jolla Cancer Research Center	Peptides for reducing or inhibiting bone resorption
US5688781A (en) *	1994-08-19	1997-11-18	Bristol-Myers Squibb Company	Method for treating vascular leak syndrome
EP0833934B2 (en)	1995-06-15	2012-08-15	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
AR022303A1 (es) *	1999-01-22	2002-09-04	Lundbeck & Co As H	Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en)	1999-04-23	2000-10-25	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
WO2000065088A2 (en)	1999-04-26	2000-11-02	Amersham Pharmacia Biotech Ab	Primers for identifying typing or classifying nucleic acids
IL145941A (en)	1999-04-28	2007-08-19	Univ Texas	Preparations and methods for the treatment of cancer by selective inhibition of VEGF
AU5147700A (en)	1999-05-19	2000-12-05	Amgen, Inc.	Crystal of a lymphocyte kinase-ligand complex and methods of use
NZ517426A (en)	1999-08-27	2004-04-30	Sugen Inc	Phosphate mimics and methods of treatment using phosphatase inhibitors
US6589758B1 (en)	2000-05-19	2003-07-08	Amgen Inc.	Crystal of a kinase-ligand complex and methods of use
CA2420045A1 (en)	2000-09-27	2002-04-04	The Procter & Gamble Company	Melanocortin receptor ligands
WO2003082263A1 (en) *	2002-03-29	2003-10-09	Ontogen Corporation	Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7507568B2 (en)	2002-09-25	2009-03-24	The Proctor & Gamble Company	Three dimensional coordinates of HPTPbeta
US7226755B1 (en)	2002-09-25	2007-06-05	The Procter & Gamble Company	HPTPbeta as a target in treatment of angiogenesis mediated disorders
US20050154011A1 (en) *	2003-02-20	2005-07-14	The Procter & Gamble Company	Tetrahydroisoquinolnyl sulfamic acids
US7588924B2 (en)	2006-03-07	2009-09-15	Procter & Gamble Company	Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
KR20110122881A (ko)	2006-04-07	2011-11-11	워너 칠콧 컴퍼니 엘엘씨	인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7589212B2 (en)	2006-06-27	2009-09-15	Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) *	2006-06-27	2010-09-14	Warner Chilcott Company	Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) *	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
US7769557B2 (en) *	2008-07-01	2010-08-03	Honeywell International Inc.	Multi-gas flow sensor with gas specific calibration capability
CN102365023A (zh)	2009-01-12	2012-02-29	阿克比治疗有限公司	治疗血管渗漏综合征的方法
PT2451279T (pt)	2009-07-06	2019-06-18	Aerpio Therapeutics Inc	Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas

2007
- 2007-06-26 US US11/821,846 patent/US7795444B2/en active Active
- 2007-06-27 EP EP17187910.9A patent/EP3293182A1/en not_active Withdrawn
- 2007-06-27 SI SI200731650T patent/SI2038265T1/sl unknown
- 2007-06-27 WO PCT/US2007/014823 patent/WO2008002570A2/en active Application Filing
- 2007-06-27 ES ES07809908.2T patent/ES2534392T3/es active Active
- 2007-06-27 HU HUE07809908A patent/HUE024976T2/en unknown
- 2007-06-27 JP JP2009518227A patent/JP5261383B2/ja not_active Expired - Fee Related
- 2007-06-27 DK DK07809908.2T patent/DK2038265T3/en active
- 2007-06-27 CA CA2657107A patent/CA2657107C/en active Active
- 2007-06-27 EP EP07809908.2A patent/EP2038265B1/en not_active Not-in-force
- 2007-06-27 PL PL07809908T patent/PL2038265T3/pl unknown
- 2007-06-27 EP EP12196179.1A patent/EP2592073B1/en not_active Not-in-force
- 2007-06-27 NZ NZ574406A patent/NZ574406A/en not_active IP Right Cessation
- 2007-06-27 BR BRPI0713357-0A patent/BRPI0713357A2/pt not_active Application Discontinuation
- 2007-06-27 MX MX2009000289A patent/MX2009000289A/es active IP Right Grant
- 2007-06-27 AU AU2007265454A patent/AU2007265454B2/en not_active Ceased
- 2007-06-27 PT PT78099082T patent/PT2038265E/pt unknown
- 2007-06-27 KR KR1020097001694A patent/KR101179087B1/ko not_active Expired - Fee Related
2008
- 2008-12-23 IL IL196129A patent/IL196129A/en active IP Right Grant
2009
- 2009-01-27 CO CO09007334A patent/CO6150140A2/es unknown
- 2009-09-10 HK HK09108320.5A patent/HK1129387A1/xx not_active IP Right Cessation
2010
- 2010-08-04 US US12/850,026 patent/US8106078B2/en not_active Expired - Fee Related
2011
- 2011-12-01 US US13/309,445 patent/US8329916B2/en not_active Expired - Fee Related
2013
- 2013-02-19 JP JP2013029649A patent/JP2013091669A/ja not_active Withdrawn
2015
- 2015-05-08 CY CY20151100409T patent/CY1116377T1/el unknown
- 2015-09-10 JP JP2015178320A patent/JP2016026176A/ja not_active Withdrawn
- 2015-09-10 JP JP2015178321A patent/JP2015221837A/ja active Pending
2017
- 2017-11-06 JP JP2017213854A patent/JP2018048190A/ja not_active Withdrawn
- 2017-11-06 JP JP2017213855A patent/JP2018016657A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CO6150140A2 (es)	2010-04-20
MX2009000289A (es)	2009-03-20
EP2592073A2 (en)	2013-05-15
WO2008002570B1 (en)	2008-04-17
BRPI0713357A2 (pt)	2012-03-06
AU2007265454A2 (en)	2009-04-30
JP2015221837A (ja)	2015-12-10
IL196129A (en)	2013-03-24
CA2657107A1 (en)	2008-01-03
HUE024976T2 (en)	2016-02-29
AU2007265454A1 (en)	2008-01-03
HK1129387A1 (en)	2009-11-27
EP2592073A3 (en)	2013-05-29
JP2009542659A (ja)	2009-12-03
US8106078B2 (en)	2012-01-31
CA2657107C (en)	2014-01-07
SI2038265T1 (sl)	2015-06-30
EP2038265B1 (en)	2015-03-18
EP3293182A1 (en)	2018-03-14
EP2038265A2 (en)	2009-03-25
US20080004267A1 (en)	2008-01-03
IL196129A0 (en)	2009-09-22
JP5261383B2 (ja)	2013-08-14
CY1116377T1 (el)	2017-02-08
WO2008002570A2 (en)	2008-01-03
JP2016026176A (ja)	2016-02-12
AU2007265454B2 (en)	2011-10-27
DK2038265T3 (en)	2015-04-20
JP2018016657A (ja)	2018-02-01
ES2534392T3 (es)	2015-04-22
NZ574406A (en)	2012-01-12
EP2592073B1 (en)	2017-08-30
US7795444B2 (en)	2010-09-14
US20110212951A1 (en)	2011-09-01
WO2008002570A3 (en)	2008-02-14
JP2018048190A (ja)	2018-03-29
US20120077975A1 (en)	2012-03-29
JP2013091669A (ja)	2013-05-16
PT2038265E (pt)	2015-05-21
US8329916B2 (en)	2012-12-11
KR101179087B1 (ko)	2012-09-07
KR20090024820A (ko)	2009-03-09

Publication	Publication Date	Title
PL2038265T3 (pl)	2015-07-31	Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i sposoby stosowania
HK1129388A1 (en)	2009-11-27	Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use
DK3323815T3 (en)	2021-01-11	Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
EP2091588A4 (en)	2010-05-26	CARDIAL DEVICE AND USE METHOD THEREFOR
IL196956A0 (en)	2009-11-18	Aza-benzofuranyl compounds and methods of use
EP2191458A4 (en)	2012-02-15	FINGER-FITTED DEVICES AND METHODS OF USE THEREOF
HK1147254A1 (en)	2011-08-05	5-anilinoimidazopyridines and methods of use 5-
IL197060A0 (en)	2009-11-18	Aza-benzothiophenyl compounds and methods of use
EP2023718A4 (en)	2010-04-21	CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
EP2021455A4 (en)	2014-01-01	SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
EP2026843A4 (en)	2011-06-22	THERAPEUTIC USES OF RTP801L INHIBITORS
IL194028A0 (en)	2009-09-22	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL193693A0 (en)	2009-05-04	Purine compounds and methods of use thereof
GB0719577D0 (en)	2007-11-14	Microimplant devices and methods of making and use thereof
IL206125A0 (en)	2010-11-30	Azaindolizines and methods of use
ZA200900203B (en)	2013-06-26	Adjuvants and methods of use
GB0608647D0 (en)	2006-06-14	Methods of diagnosis and treatment
IL206891A0 (en)	2010-12-30	Therapeutic inhibitors of pai-1 function and methods of their use
ZA200900896B (en)	2010-06-30	Aza-benzofuranyl compounds and methods of use
ZA200900492B (en)	2010-06-30	Human protein tyrosine phosphatase inhibitors and methods of use
ZA200901009B (en)	2010-05-26	Aza-benzothiophenyl compounds and methods of use
GB0603497D0 (en)	2006-04-05	Device and method of use
ZA200807956B (en)	2009-07-29	Purine compounds and methods of use thereof
IL195722A0 (en)	2009-09-01	Therapeutic uses of inhibitors of rtp801l